Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00193245
Status:
COMPLETED
Last Update Posted:
2010-06-28
First Post:
2005-09-12
Brief Title:
Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC
Study Overview
Official Title:
A Randomized Trial of Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2009-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this trial we will evaluate and compare the efficacy and toxicity of oral topotecan with intravenous docetaxel in the second-line treatment of patients with non-small cell lung cancer
Detailed Description:
Upon determination of eligibility patients will be randomly assigned to one of two treatment arms
Topotecan
Docetaxel
For ever 2 patients treated 1 will receive treatment A Topotecan and 1 will receive treatment B Docetaxel The study is not blinded so both the patient and the doctor will know which treatment has been assigned
Topotecan
Docetaxel
For ever 2 patients treated 1 will receive treatment A Topotecan and 1 will receive treatment B Docetaxel The study is not blinded so both the patient and the doctor will know which treatment has been assigned
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 104864-450 | None | None | None |